AbbVie (NYSE: ABBV) is on its way to becoming a pharmaceutical giant. It's set to hold the biggest share of the prescription drug market by 2026, according to Evaluate Pharma. It's in the No. 7 position today, so the company would be making quite a jump.
At the same time, AbbVie is about to lose patent protection of its blockbuster immunology drug Humira. Considering all of this, should we bullish or bearish on the stock? Motley Fool contributors Adria Cimino and Keith Speights present both sides of the argument.
Adria Cimino: AbbVie's immunology portfolio is going strong, even with the Humira patent expiration on the horizon. The company says the combined peak sales of immunology drugs Rinvoq and Skyrizi will surpass Humira's peak sales. That's as the company gains approval for those drugs in all of Humira's indications. So the future of this portfolio looks bright.
Source Fool.com